Currently Viewing:
Currently Reading
Solriamfetol Launches With Schedule IV Designation, Phase 3 Study Results
August 19, 2019 – Christina Mattina
Insomnia Correlated to an Increased Risk of Heart Disease and Stroke, Study Shows
August 19, 2019 – Matthew Gavidia
Unmet Care Targets Suggest Need for Improved Diabetes Care Accessibility
August 18, 2019 – Alison Rodriguez
Inspiratory Muscle Training May Be an Option for Patients Who Decline Pulmonary Rehabilitation for COPD
August 18, 2019 – Kelly Davio
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019

Repatha, Amgen's PCSK9 Competitor, Gains FDA Approval

Mary K. Caffrey
The approval of evolocumab (Repatha) creates competition in the new class of PCSK9 cholesterol-fighting therapies and managed care plans and pharmacy benefit managers are expected to take full advantage to hold down costs.
The FDA today approved evolocumab, Amgen’s entrant into the PCSK9 inhibitor frenzy, a month after giving the green light to Sanofi-Regeneron’s alirocumab and setting up standoffs with pharmacy benefits managers (PBMs) over what they will pay for these revolutionary but expensive cholesterol-lowering drugs.

Evolocumab, to be sold as Repatha, gained approval for indications similar those FDA gave on July 24, 2015, to alirocumab, being sold as Praluent. Repatha was approved for use in addition to diet and maximally-tolerated stain therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of low-density lipoprotein (LDL) cholesterol.

Alirocuamb was approved to treat patients with familial hypercholesterolemia, as well as high-risk patients with demonstrated heart disease whose cholesterol has not been controlled with maximally tolerated statins.

It is expected that managed care plans and PBMs will have highly specific protocols to determine who gains access to the drug, given its price. Amgen announced late in the day that it will list the wholesale price of Repatha at $14,100 a year, just below Sanofi-Regeneron's annual price of $14,600 for Praluent.  CVS Health announced August 10, 2015, it would refuse to negotiated prices for the new drug class until after today’s FDA action, when it could work with 2 competitors. 

In a press release, Amgen said the wholesale price would be for dosing of 140 mg by injection every 2 weeks. A once-a-month option of 420 mg is expected to be available next year.

With both drugs being priced well above analysts' estimates, PBMs are ready to negotiate. Late yesterday, Express Scripts' Chief Medical Officer Steve Miller, MD, said in a statement that the PBM's pharmacy and therapeutics committee will be reviewing both drugs next month, and will announce decisions on covering 1 or both drugs after that process. "While a drug exclusion remains a possibility, our preference would be that both manufacturers provide our clients with favorable pricing so that it would make sense for our national formulary to cover both products. We would only exclude one if our P&T committee determines that the product we cover is at least clinically equivalent to the one we exclude. And only then would we exclude one of these products if that exclusion would deliver significant savings for our clients and patients."

Until that time, Miller said, the PCSK9 inhibitors will be availble through an medical exception process that ensures "their use is restricted only to those for whom the products are clinically appropriate and in line with FDA recommendations."

FDA regulators did not go as far in approving evolocumab as European regulators have. While the drug was second to be approved here, it beat alirocumab to the finish line overseas in late July. The European Commission allowed broader indications including for those unable to tolerate statins, a key patient group that evolocumab’s sponsors in particular had hoped to target when presenting data on the drug to an FDA advisory committee in June. Amgen will present additional data on the effects of the drug on this population at a conference in London next week.

Like its competitor, evolocumab is an injectable monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme that when blocked results in dramatically lower levels of LDL cholesterol. PCSK9 prevents the liver from effectively eliminating LDL cholesterol on its own. The discovery that persons who lacked this enzyme had abnormally low cholesterol levels triggered wave of research to unleash the therapeutic potential, as pharmaceutical sponsors began looking for ways to block PCSK9.

Evolocumab dazzled attendees at the 2014 meeting of the American College of Cardiology (ACC) with 3 studies that showed the therapy lowering cholesterol between 55% and 62% for various conditions, including heterozygous familial hypercholesterolemia.

The most recent clinical findings for evolocumab were presented at ACC this past March, when Marc Sabatine, MD, MPH, of Brigham and Women’s Hospital outlined preliminary safety data as well as additional results to confirm the drug’s effects on lowering cholesterol. Compared with standard therapy along, patients taking evolocumab saw LDL cholesterol reduced 61%, and the rate of cardiovascular events at 1 year was reduced from 2.18% in the standard therapy group to 0.95% in the evolocumab group. However, these results are only after 11 months, and FDA likely will not expand the drug’s indications until after results from a long-term safety trial of 27,500 patients appear in 2017.

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up